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Complementary and alternative medicine is used by many cancer patients in most parts of the world, and
its use is increasing. The aim of the present study was to examine, over 5 years, the perceived quality of
life/life satisfaction in two samples of women with breast cancer who were treated with anthroposophic
care or conventional medical treatment only. Data from admission, after 1 year and after 5 years are used
for the comparisons. On admission to the study the women in anthroposophic care perceived their
quality of life to be lower than that of the women in the conventional treatment group, especially for
emotional, cognitive and social functioning and overall quality of life. Sixty women who actively chose
treatment with anthroposophic medicine and 60 individually matched women treated with conventional
medicine participated. Quality of life was measured by the EORTC QLQ-C30 and the Life Satisfaction
Questionnaire. Twenty-six women within anthroposophic care and 31 women within conventional
medicine survived the 5 years. Effect size (ES) estimation favored the anthroposophic group in seven
of the subscales mostly measuring emotional functioning. The ES for four of the subscales favored the
conventional treatment group, mostly concerning physical functioning. After 5 years there were
improvements in overall quality of life and in emotional and social functioning compared to admission
for the women in anthroposophic care. The improvements took place between admission and 1 year, but
not further on. Only minor improvements were found in the matching group.
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Introduction
The Use of Complementary and Alternative Medicine
Complementary and alternative medicine (CAM) is used by
many cancer patients in most parts of the world, and its use
is increasing (1). Eisenberg et al. (2) found in a national survey
of the use of alternative therapies in 1997 in the USA, that
the range of use varied between 32 and 54% in different
sociodemographic groups and that the use had increased 45%
between 1990 and 1997. A cross-sectional study in Europe of
956 cancer patients in 14 countries showed that  36% had
used CAM (3). Studies show that people who choose CAM
differ from those who choose conventional medicine. A
review of the literature show that CAM users tend to be better
educated, of higher socioeconomic status, female and younger
than non-users (4,5). Studies also show that seeking alternative
treatment is more common among mentally distressed cancer
patients (6,7).
A multicenter study from Norway showed survival data for a
follow-up of 8 years for 515 cancer patients. The survival rate
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compared with non-users, 35%. The authors concluded that
AM use may predict a shorter survival (8).
Anthroposophic Care in Sweden
In Sweden there is one anthroposophic hospital situated in the
county of Stockholm. It has 74 beds and  3000 out-patients
yearly. About 40% of the patients suffer from cancer (9). The
patients actively seek this form of care themselves, but the fee
is most often provided by the county council.
In anthroposophic medicine, natural scientific methods used
in conventional medicine are not contraindicated. In order to
reach true healing, however, the patient must be given the
opportunity to mature through the complementary use of
anthroposophic therapies. The term ‘complementary’ signifies
that conventional therapy can be part of the treatment (10).
The Present Study
The present study is part of a major clinical study of the
outcome of anthroposophic medicine, for women with breast
cancer. By matching procedures, women with breast cancer
not receiving complementary care are also studied, as is
the relationship between different outcome measurements
(11). The following outcome measures were used in the main
study: (i) the perceived quality of life/life satisfaction and
coping measured by questionnaires and tape-recorded inter-
views; (ii) medical investigation; and (iii) an immunological
test package. The patients have been followed for 5 years. The
design was based on prestudies performed in 1988–1994 (9).
The subjects in the major clinical study were women
diagnosed with breast cancer that chose the anthroposophic
hospital for treatment and individually matched women with
breast cancer treated with conventional medicine only. A
power analysis was performed on the basis of quality of life
measurements in an earlier study where the Life Satisfaction
Questionnaire (LSQ) was developed. In that study, 362 women
with breast cancer filled out the EORTC QLQ-C30 and the
LSQ (12). A sample size of 60 in each group was required to
detect a difference of 0.5SD with apowerof0.80. Adifference
of 0.5 SD for overall quality of life was considered big enough
to give relevant information according to Anthony (13).
The results of the comparison between the two groups on
admission and at the 1 year follow-up have been presented
elsewhere (14,15). On admission to the study the women who
choose anthroposophic care perceived their quality of life to be
lower than that of the women in the conventional treatment
group, especially for emotional, cognitive and social function-
ing and overall quality of life (14). The results from the 1 year
follow-up showed that 36 matched pairs took part on all
measurement occasions, and the patients choosing anthropo-
sophic care showed increased quality of life/life satisfaction
than those who received conventional treatment only in the
scales/factors measuring physical, emotional, cognitive, social
functioning and quality of daily activities and also less
problem with sleep and appetite after 1 year compared with
admission to the study (15).
The Aim of the Study
The aim of the present study was to examine, over 5 years, the
perceived quality of life/life satisfaction in two samples of
women with breast cancer who were treated with anthropo-
sophic care or conventional medical treatment only. Data from
admission, after 1 year and after 5 years are used for the
comparisons.
Methods
Design and Participants
The subjects were women diagnosed with breast cancer who
chose the anthroposophic hospital for treatment. Sixty women
who met the inclusion criteria, i.e. 75 years old, or younger,
residing in Stockholm, being able to communicate in Swedish,
and expected to live for at least 6 months, were admitted from
November 1995 to January 1999. In all, 68 women were
invited to participate. Each woman was individually matched
with a woman from an oncology out-patient department in
the southern Stockholm area who received conventional
medical cancer treatment. A total of 120 women were
included. The matching criteria were based on the following
principles: (i) stage of disease at entry—advanced inoperable
tumor or distant metastases (n ¼ 42 þ 42) or operable tumors
with or without node metastases (n ¼ 18 þ 18); (ii) age—over
50 years (n ¼ 20 þ 20) or 50 years or younger (n ¼ 40 þ 40);
(iii) treatment during the 3 months before entering the
study—radiotherapy or chemotherapy (n ¼ 41 þ 41) or no
treatment (n ¼ 19 þ 19); and (iv) prognosis—favorable
prognosis (35 þ 35) or unfavorable (n ¼ 25 þ 25). Prognosis
was related to the frequency and location of metastases.
Prognosis was only applied as a matching variable in cases
with metastatic disease. The groups were called ABCW
(women with breast cancer in anthroposophic care) and
CBCW (women with breast cancer in conventional care).
The women were between 28 and 75 years of age (M ¼ 49.2,
SD ¼ 9.1) on entering the study (M ¼ 49.4, SD ¼ 9.7, range ¼
28–75 and M ¼ 49.1, SD ¼ 8.5, range ¼ 29–70, respectively.
Sixty-seven percent (n ¼ 40) of the women who chose
anthroposophic care (ABCW) and 78% (n ¼ 47) in the other
group (CBCW) were married or lived with a partner, and 75%
(n ¼ 45, ABCW) and 85% (n ¼ 51, CBCW) had children.
Time between diagnosis and admission to the study varied
between 1 and 128 months for the women choosing anthro-
posophic care (M ¼ 32.57, SD ¼ 31.6) and between 1 and 238
months for the women in conventional treatment (M ¼ 36.92,
SD ¼ 45.3). There was no significant difference between the
two groups in these respects. Table 1 shows the frequency of
women in the two groups who took part on the different
occasions. Eight women dropped out of the study in the
ABCW, but at the 5 year follow-up, three of those women
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dropped out of the study. One reason the women gave for
declining to further participate after inclusion was that they
felt it was too demanding to be interviewed and fill out
questionnaires several times. Progressions of the disease or
other medical problems were other reasons. Furthermore,
some women did not reply to the invitation to take part in
the 6 month, 1 year or 5 year follow-up.
Measures
The EORTC QLQ-C30
This consists of 30 items expressed in six functional scales
(PF, physical functioning; RF, role functioning; EF, emotional
functioning; CF, cognitive functioning; SF, social functioning;
and QL, global quality of life) and nine symptom scales (FA,
fatigue; NV, nausea and vomiting; PA, pain; DY, dyspnea;
SL, sleep disturbance; AP, appetite loss; CO, constipation; DI,
diarrhea; and FI, financial impact). In the present study, the
Swedish edition of version 1.0 of the instrument was used (16).
The scores on the functional scales are linearly transformed
such that all scales range from 0 to 100, with a higher score
representing a higher level of functioning. The symptoms scale
items are also linearly transformed such that all scales/items
range from 0 to 100. Higher scores represent a higher level of
symptomatology/problems (16).
The LSQ
The LSQ consists of 34 items on 7-point scales. Examples:
‘How much have you been troubled by tiredness during the
past week?’ Responses range from ‘1’, very much,t o‘ 7’, not at
all. Scale point 7 represents the highest quality in all items.
The 34 items are allocated to six different factors as follows:
physical symptoms (PS), sickness impact (SI), quality of
daily activities (QDA), socioeconomic situation (SES), quality
of family relation (QFA) and quality of close friend relation-
ship (QFR). The scores for each factor are calculated as
follows: the raw scores of the items are summarized, divided
by the highest point in the scale and multiplied by 100. Thus,
100 represents the maximum quality in each factor. The total
quality of life/life satisfaction is calculated in the same
way (17,18).
Interventions
Both groups had been treated according to a special regional
care program for all patients belonging to the Stockholm/
Gotland region (19). The women who chose anthroposophic
care were additionally treated with a special care program
during their stay at the anthroposophic hospital (mean value
14.3 days, range 5–29 days). The individually composed
anthroposophic therapies consisted of holistic care including
natural products, Iscador, diets, art therapy, rhythmic therapy,
therapeutic massage and hydrotherapy (10). The anthropo-
sophic hospital, built in 1985, is small with 74 beds. The
hospital is situated in the countryside outside of Stockholm.
The caring environment is by many patients considered as
peaceful, ‘almost like a monastery or a retreat’. Television
and radio are not available and phones are advised to be used
sparsely. The aim of caring is to find rest and peace and good
encounters with self and others, caring personnel as well as
fellow patients. Bodily therapies, art therapies, anthroposophic
and conventional medicines are individually prescribed by the
responsible physician. The caring personnel consist of regis-
tered nurses and therapists specially trained in anthroposophic
medicine and care.
Procedure
The women were followed for 5 years and were assessed by
the questionnaires on six occasions as follows: on admission,
after 1 month, after 3 months, after 6 months, after 1 year and
after 5 years. Data from admission, after 1 year and after
5 years are used in the present study.
Data Analysis
Analysis of variance (ANOVA) for repeated measure within
each group was used to identify significant differences,
Bonferroni correction was used for the post-tests in order
to control for mass significance. Effect size (ES) was used
for comparisons between groups. A value close to 1 indicates
that all variability is attributable to the difference between
Table 1. The frequency of women who answered the EORTC QLQ-C30 and the LSQ on different occasions in ABCW and CBCW
Occasion ABCW CBCW Matched
pairs Participants Deceased
† Dropouts Participants Deceased Dropouts
Admission 60 60 60
After 4 weeks 53 1 6 58 2 52
After 3 months 51 3 6 55 3 2 48
After 6 months 48 6 6 53 5 2 44
After 1 year 41 11 8 47 9 4 36
After 5 years 21 34 5
z 23 29 8 13
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
†Cumulative frequency.
zThree of the eight women who were dropouts during the first year died before the 5 year follow-up.
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that little of the variability is explained (20). According to
Cohen (21), an ES >0.20 should be considered small, an
ES between 0.50 and 0.80 moderate, and an ES >0.80 large.
SPSS version 11.0 was used for the statistical procedures.
Ethical Considerations
The main project had been approved after ethical investigation
by the Regional Research Ethics Committee at the Karolinska
Institute, Stockholm, in 1995 and 2001.
Results
Survival
Twenty-six (43%) of the women who chose anthroposophic
care and 31 (52%) of the women in the other group survived
the data collection period. This difference is not statistically
significant (Wilcoxon’s signed rank test, Z ¼  1.508, P ¼
0.132). The cumulative survival is shown in Fig. 1.
Time since diagnosis varied in both groups (range 1–128
months in ABCW and 1–238 months in CBCW). It means
that survival time since diagnosis varied a lot in both groups.
To use time since diagnosis as a covariate did not change the
result. There was no statistically significant difference in
survival between the two groups after 5 years (P ¼ 0.134).
Quality of Life Over Time
On admission there were significant differences between the
two groups (n ¼ 60 þ 60) in several of the scales of EORTC
QLQ-30 (RF, EF, CF, SF, QL, FA, PA and FI) and in some of
the factors of the LSQ (PS, SI, SES and TotQoL) (14).
ABCW
Changes over time calculated with the help of ANOVAs
showed some significant changes within the ABCW (n ¼ 21).
In the EORTC QLQ-C30 there were significant improvements
in four of the functional scales (EF, CF, SF and QL) and in four
of the symptoms scales (FA, NV, PA and DY) (see Tables 2
and 3). Most improvements were seen between admission
and 1 year, but not further on. In the LSQ there were
significant improvements in four of the factors and in the total
scale (PS, SI, QDA, SES and TotQL) (see Table 4). The
Figure 1. Cumulative survival during 5 years for ABCW and CBCW,
respectively.
Table 2. The means, standard deviations, F and P-values (Wilks lambda and Bonferroni correction) for the scales of the EORTC QLQ-C30, functional scales,
for admission, after 1 year and after 5 years
Scale ABCW (n ¼ 21) CBCW (n ¼ 23)
Admission 1 year 5 years Admission 1 year 5 years
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
PF 80.00 22.8 84.26 15.7 78.10 26.8 80.87 19.5 84.33 15.9 80.00 19.1
RF 59.53 34.0 71.43 29.9 66.67 32.9 76.09 25.3 73.91 29.7 65.22 38.2
EF 54.76 18.7 73.41 16.6 67.10 19.9 72.83 25.5 66.39 30.1 72.46 27.1
CF 66.67 26.4 84.13 14.4 80.16 22.1 76.09 26.5 73.23 28.7 78.26 24.3
SF 61.11 28.1 83.33 21.7 78.57 28.5 80.43 21.1 73.26 29.2 80.43 30.4
QL 46.43 20.7 66.65 15.8 67.86 19.1 61.23 28.0 60.19 29.17 69.20 24.5
Scale FPSignificance* FP Significance*
PF 2.083 0.152 n.s. 0.892 0.078 n.s.
RF 1.160 0.335 n.s. 1.220 0.104 n.s.
EF 14.670 <0.001 1–2** 1.522 0.241 n.s.
CF 7.099 0.005 1–2, 1–3*** 0.447 0.645 n.s.
SF 7.140 0.005 1–2 1.022 0.377 n.s.
QL 16.553 <0.001 1–2, 1–3 1.612 0.223 n.s.
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
*P < 0.05 for significant difference; **1–2 ¼ admission versus 1 year; ***1–3 ¼ admission versus 5 years.
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for admission, after 1 year and after 5 years
Scale ABCW (n ¼ 21) CBCW (n ¼ 23)
Admission 1 year 5 years Admission 1 year 5 years
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
FA 55.56 23.6 33.86 20.0 40.74 28.8 35.27 23.4 40.10 30.7 30.43 26.0
NV 13.49 20.2 7.14 16.3 1.59 5.0 6.52 17.2 9.42 20.0 3.62 7.0
PA 39.68 29.1 17.46 18.6 22.22 27.0 25.36 29.7 24.68 29.3 23.19 33.2
DY 28.57 30.3 28.57 26.4 26.90 32.7 30.43 28.3 30.43 31.6 20.13 19.3
SL 41.27 27.7 26.98 27.1 38.10 32.1 28.79 36.1 31.86 31.7 30.30 35.5
AP 14.29 27.0 3.17 10.0 4.76 12.0 4.35 11.5 11.60 21.6 0.00 0.0
CO 22.22 28.5 15.87 22.7 17.46 25.0 10.14 23.4 5.80 16.4 8.70 15.0
DI 7.94 14.5 1.59 7.3 11.67 19.1 5.80 16.4 10.14 21.2 10.14 25.5
FI 42.86 46.1 36.51 40.7 28.57 33.8 18.84 22.1 17.05 24.3 18.84 33.1
Scale FPSignificance* FPSignificance*
FA 7.099 0.005 1–2** 1.157 0.334 n.s.
NV 4.036 0.035 1–3*** 1.232 0.312 n.s.
PA 10.882 0.001 1–2, 1–3 0.115 0.892 n.s.
DY 0.047 0.954 n.s. 2.275 0.128 n.s.
SL 2.140 0.145 n.s. 0.121 0.887 n.s.
AP 1.947 0.170 n.s. 5.966 0.009 n.s.
CO 0.684 0.517 n.s. 0.287 0.754 n.s.
DI 5.428 0.014 n.s. 2.405 0.115 n.s.
FI 1.406 0.270 n.s. 0.313 0.734 n.s.
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
*P < 0.05 for significant difference; **1–2 ¼ admission versus 1 year; ***1–3 ¼ admission versus 5 years.
Table 4. The means, standard deviations, F and P-values (Wilks lambda and Bonferroni correction) for the factors of the LSQ for admission, after 1 year and
after 5 years
Scale ABCW (n ¼ 21) CBCW (n ¼ 23)
Admission 1 year 5 years Admission 1 year 5 years
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
PS 84.26 13.5 90.30 10.5 87.66 12.3 89.44 10.3 88.91 12.5 91.05 11.2
SI 57.82 13.9 68.38 14.0 65.76 17.4 70.08 19.5 69.05 24.5 69.88 23.1
QDA 58.70 14.8 75.32 13.8 72.98 19.8 69.03 17.7 71.22 16.1 74.71 12.4
SES 63.66 16.6 73.47 17.0 72.79 15.3 74.35 12.6 70.37 17.1 77.44 16.5
QFA 73.47 16.2 73.74 13.6 75.65 13.7 76.03 16.5 71.30 17.4 76.05 17.0
QFR 77.14 10.4 74.29 12.2 78.50 10.2 78.73 13.8 77.11 11.2 70.56 21.2
TotQL 69.17 9.1 75.92 10.0 75.56 10.2 76.26 10.9 74.47 13.1 76.46 11.4
Scale FPSignificance* FPSignificance*
PS 4.191 0.031 1–2** 2.086 0.149 n.s.
SI 7.353 <0.001 1–2, 1–3** 0.044 0.957 n.s.
QDA 14.127 <0.001 1–2, 1–3 1.106 0.349 n.s.
SES 32.541 <0.001 1–2, 1–3 4.603 0.022 2–3****
QFA 0.236 0.792 n.s. 1.223 0.314 n.s.
QFR 0.960 0.401 n.s. 1.621 0.221 n.s.
TotQL 18.409 <0.001 1–2, 1–3 0.465 0.634 n.s.
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
*P < 0.05 for significant difference; **1–2, admission versus 1 year; ***1–3, admission versus 5 years; ****2–3, 1 year versus 5 years.
eCAM 2006;3(4) 527improvements were seen between admission and 1 year but not
further on.
CBCW
Changes over time calculated with the help of ANOVAs
showed no significant change within the CBCW (n ¼ 23) in
any of the scales of the EORTC QLQ-C30, see Tables 2
and 3. There was one significant improvement in SES in the
LSQ, between 1 and 5 years, see Table 4.
Comparison Between the 13 Matched Pairs of the
ABCW and the CBCW
Table 5 presents the ES for the differences between the
admission and the comparison after 5 years. There were small
to moderate effects in nine of the scales of the EORTC
QLQ-C30 (PF, RF, EF, CF, NV, PA, DY, AP and CO). In the
LSQ, there was a small effect in SES and a large effect in QFR.
For some scales/factors, the ES was attributable to improve-
ment in one group and deterioration in the other; in others there
were improvement in both groups but the improvement was
greater in one of the groups, and still in others there was no
change in one group but improvement in the other. The ES
for seven of the scales/factors were in favor of the ABCW
(RF, EF, CF, NV, PA, SES and QFR), and favored the CBCW
for four of the scales/factors (PF, DY, AP and CO) (see
Table 5).
The Outcome of the Matching Procedure
In Table 6, prognosis on admission to the study is shown in
relation to 5 year survival. Of those with favorable prognosis
on admission to the study, 73% were still alive after 5 years
and 27% were deceased. Of those with unfavorable prognosis
on admission, 88% were deceased and 12% were still alive
Table 5. The effect sizes (ES) after 5 years, means and standard deviations for the comparison of the scales of the EORTC QLQ-C30 and the factors of
the LSQ (n ¼ 13 matched pairs)
ES
† ABCW CBCW
Admission 5 years Admission 5 years
Mean SD Mean SD Mean SD Mean SD
EORTC QLQ-C30
Functional
PF
z  0.30 81.54 22.3 76.92 33.5 80.00 20.0 83.08 19.7
RF
x 0.47 50.00 35.4 65.38 37.6 76.92 25.9 65.38 42.7
EF
x 0.24 54.49 18.2 67.31 22.2 66.67 26.8 70.51 30.4
CF
x 0.22 64.10 24.4 79.49 24.7 74.36 28.6 79.49 21.7
SF 0.12 66.67 27.2 74.36 33.8 82.05 22.0 84.62 28.4
QL 0.18 44.87 19.4 65.38 21.7 56.41 34.0 69.23 21.3
Symptom
FA  0.04 58.35 20.7 42.72 33.9 38.46 26.7 29.06 28.9
NV
x  0.23 10.26 18.7 1.28 4.6 6.41 14.5 2.56 6.3
PA
x  0.48 46.15 29.0 20.51 26.5 28.21 33.6 25.64 37.0
DY
z 0.27 17.94 22.0 23.00 36.9 23.08 28.5 17.77 17.1
SL 0.05 41.03 24.2 43.59 34.4 35.90 34.6 35.90 39.6
AP
z 0.27 5.13 12.5 5.13 12.5 5.12 12.5 0.00 0.0
CO
z 0.22 17.95 22.0 17.95 25.9 15.38 29.2 7.69 14.6
DI  0.13 12.82 16.9 13.72 21.3 10.26 21.0 15.38 32.2
FI 0.00 38.46 46.8 33.33 36.0 25.04 24.2 20.51 39.8
LSQ
PS 0.01 86.97 11.9 88.38 14.1 88.22 11.2 89.50 12.2
SI 0.10 57.88 11.6 64.65 19.9 68.13 20.9 72.16 24.7
QDA 0.02 60.13 14.9 71.23 21.9 67.82 20.3 76.29 12.1
SES
x 0.28 66.02 14.1 71.98 15.7 74.45 14.2 75.55 20.1
QFA 0.16 70.33 18.2 73.36 14.9 72.09 17.9 71.47 19.1
QFR
x 0.88 75.38 11.5 78.24 10.3 74.95 14.7 64.40 24.5
TotQL 0.15 69.45 8.5 74.35 11.6 74.28 12.1 74.90 12.9
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
†ES ¼ 0.20–0.50, small; ES ¼ 0.50–0.80, moderate; ES > 0.80, large (22).
zIn favor of the CBCW.
xIn favor of the ABCW.
528 Quality of Life in breast cancer over 5 yearsafter 5 years. The outcome in terms of survival in relation to
prognosis on admission was in total 79% (82% for ABCW and
77% for CBCW).
For 49 of the 60 matched pairs, the outcome was the same:
26 were deceased and 23 alive after 5 years. For the remaining
11 pairs, 8 women who had chosen anthroposophic care died
and their matched twins in conventional treatment were alive,
and 3 women in anthroposophic care were alive, whereas their
matched twins in conventional treatment had died.
Discussion
As reported earlier, the women who chose anthroposophic care
rated their quality of life/life satisfaction lower on entering the
study than that of the women in the conventional treatment
group (14). They also used more passive and anxious coping
compared with their matched ‘twins’ on admission to the
study. The results from the 1 year follow-up showed that the
women who took initiative to be referred to anthroposophic
care reported increased quality of life/life satisfaction after
treatment at the anthroposophic hospital compared with the
women receiving conventional treatment (15). The results of
the present study showed the same pattern; the women in
anthroposophic care still reported increased quality of life after
5 years, but the improvements were seen between admission
and 1 year and not further on.
The difference in survival rate between the two groups
after 5 years, 43% in ABCW versus 52% in CBCW, was not
statistically significant. Although the tendency toward lower
survival rate in the group in anthroposophic care is in
agreement with the results reported by Risberg et al. (8) that
the survival rate was lower for CAM users, there are no data
available in the present study that could explain this tendency.
It is important to study survival of CAM users in future studies.
The finding that the women who chose anthroposophic
treatment reported worse quality of life on admission than
those on conventional treatment is in agreement with the
outcome of other studies, showing that women who used CAM
express more psychological problems and perceive worse
quality of life (4,7).
The women treated with anthroposophic therapy expressed
increased quality of life/life satisfaction after 5years compared
with admission to the study. The improvements took place
between admission and 1 year but not further on. The women
treated with conventional care assessed the same quality of
life/life satisfaction after 5 years as on admission except for the
factor called SES, where there was an increase from one to
5 years. Of the seven scales/factors in which the ES favored the
women choosing anthroposophic care, five could be catego-
rized as emotional (RF, EF, CF, SES and QFR), whereas the
four scales in which the ES favored the women on conven-
tional treatment could be categorized as physical (PF, DY, AP
and CO) (see Table 5).
The intervention for the women in the ABCW was treatment
at the anthroposophic hospital with a special program for
 2 weeks (mean 14.2 days, range 5–29 days). This is a short
time, especially for evaluation after 5 years. There are no
systematic data covering the use of anthroposophic treatment
for the time between the intervention and the 5 year follow-up.
But according to the interview performed after 5 years, 16
of the 21 women who survived for 5 years had continued their
contact with the anthroposophic hospital. Four women had had
new treatment periods at the anthroposophic hospital and four
both new treatments periods and visits to the anthroposophic
primary health care clinic. Six women had visited the primary
health care clinic, and the remaining two had had telephone
contact.
Study Limitations
There are limitations of the study that must be considered. The
first is the design of the study. A randomized clinical study
would have been preferable, but it was not possible consider-
ing the resources available and the regulations of the Swedish
health care system. Thus, the present design with individually
matched pairs was an option. But since the women took
initiatives themselves to be referred to anthroposophic care,
there could be differences between the women in ABCW and
the women in the CBCW that were not controlled for by the
matching procedure. The women were individually matched
regarding stage of disease, age, treatment during the 3 months
before entering the study and prognosis. There were no
differences between the groups regarding children or marital
status but there was a difference regarding the professions of
the women on admission of the study (14). In the ABCW
 23% compared with none in the CBCW were working as
artists, journalists or other cultural workers. This could be one
explanation to why some of the women choose the anthropo-
sophic hospital and it could also mean that the two groups
differed psychologically. The groups were not equal regarding
quality of life assessments at baseline and there could have
been a spontaneous recovery in ABCW towards the level of
the CBCW. The phenomenon regression to the mean must
always be considered in longitudinal studies. A comparison
Table 6. The outcome of the matching procedure concerning prognosis on admission and survival after 5 years
Prognosis ABCW (n ¼ 60) CBCW (n ¼ 60)
Favorable Unfavorable Favorable Unfavorable
Still alive 25 1 26 5
Deceased 10 24 9 20
ABCW, women with breast cancer in anthroposophic care; CBCW, women with breast cancer in conventional care.
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from the Swedish population register (22) showed that both
ABCW and CBCW estimated the over all quality of life/life
satisfaction, measured by the LSQ, lower at inclusion to the
study (P < 0.001, ABCW, n ¼ 60; P ¼ 0.018, CBCW, n ¼ 60).
After 5 years there was no significant difference in over all
quality of life in ABCW or CBCW compared to Swedish
women (ABCW, n ¼ 21; CBCW, n ¼ 23).
Another limitation is the sample size and the fact that
although there were 60 matched pairs on admission there were
only 13 matched pairs who took part in the study after 5 years.
It took  4 years to include the 120 women in the study and
unfortunately it was not possible to go on for a longer time
with the inclusion. This was partly due to economical
restriction at the anthroposophic hospital. According to the
power analysis prior to the study, 60 pairs would be enough,
but 13 is of course too few. This means that there could be a
risk of Type II error.
Study Strengths
Although there are limitations, there are also some strengths
that should be mentioned. The first is that the instruments
used have been tested for reliability and validity and show
acceptable psychometric properties (16,17). The results were
almost the same measured with the two instruments. Other
strengths are the careful matching procedure and the low rate
of dropouts. The 5 year comparison showed that for 82% of the
matched pairs, the survival outcome was similar. Thus, it was
concluded that the accuracy of the matching categories on
admission of the study had been valid.
Conclusion
It was concluded that the women who had chosen a period of
care at the anthroposophic hospital, and who had survived for
5 years had increased their quality of life/life satisfaction.
After 5 years there were improvements in overall quality of life
and in emotional and social functioning compared to admis-
sion for the women in anthroposophic care. The improvements
took place between admission and 1 year, but not further on.
Only minor improvements were found in the matching group.
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